COMMUNIQUÉS West-GlobeNewswire

Stryker declares a $0.52 per share quarterly dividend
01/05/2019
Kalamazoo, Michigan, May 01, 2019 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.52 per share payable on July 31, 2019 to shareholders of record at [...]
Abeona Therapeutics présente des données précliniques démontrant un large potentiel thérapeutique de la thérapie génique AIM™ dans les maladies rétiniennes lors de l'assemblée générale annuelle de l'Association for Research in Vision and Ophthalmology
01/05/2019
NEW YORK et CLEVELAND, 01 mai 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq : ABEO), chef de file totalement intégré dans la thérapie génique et cellulaire, a annoncé aujourd'hui que l'administration [...]
Verrica Pharmaceuticals Announces Participation in Upcoming Investor Conferences
01/05/2019
WEST CHESTER, Pa., May 01, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that [...]
Nephros to Report First Quarter 2019 Financial Results on May 8, 2019
01/05/2019
SOUTH ORANGE, NJ, May 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, [...]
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
01/05/2019
Enrollment complete in Magnolia and Amaryllis studies RADNOR, Pa., May 01, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative [...]
Checkpoint Therapeutics Announces Positive Interim Clinical Results of Anti-PD-L1 Antibody Cosibelimab
01/05/2019
>40% objective response rates observed in first-line non-small cell lung cancer and cutaneous squamous cell carcinoma Well-tolerated safety profile Enrollment ongoing in expansion cohorts intended to support [...]
Translate Bio Announces $47.5 Million Private Placement
01/05/2019
LEXINGTON, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat [...]
Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit
01/05/2019
SAN DIEGO, May 01, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the company will host [...]
Strongbridge Biopharma plc Reports First Quarter 2019 Financial Results and Provides Corporate Update
01/05/2019
~ Following Type C Meeting with the U.S. Food & Drug Administration (FDA), Strongbridge Plans to Submit its New Drug Application (NDA) for RECORLEV™ (levoketoconazole) in the Third Quarter of 2020; Submission to [...]
Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases
01/05/2019
Data demonstrate that pre-symptomatic infants with SMA treated with SPINRAZA ® (nusinersen) over three years achieved motor milestones that are more consistent with normal childhood development Late-breaking data expand [...]
CURE Pharmaceutical Extends Closing Of Privately-Held Chemistry Holdings Inc. Acquisition to May 13
01/05/2019
OXNARD, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has extended the close of the previously announced [...]
Apollomics, Inc. Appoints Fabio M. Benedetti, M.D. as Chief Medical Officer
01/05/2019
FOSTER CITY, Calif. and HANGZHOU, China, May 01, 2019 (GLOBE NEWSWIRE) -- Apollomics, Inc. (the “Company”), an innovative biopharmaceutical company committed to the discovery and development of oncology combination [...]
Myriad Genetics to Present at Two Upcoming Healthcare Conferences
01/05/2019
SALT LAKE CITY, May 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that it will be presenting at two upcoming healthcare [...]
Clearside Biomedical’s Suprachoroidal Space Injection Platform Featured at Multiple Ophthalmology and Gene Therapy Medical Meetings
01/05/2019
- SCS injection platform continues to be well-received by the medical community - - Suprachoroidal administration may offer targeted delivery of gene therapies without risks of vitrectomy and subretinal surgery - [...]
EyePoint Pharmaceuticals Presents Positive YUTIQ™ 36-month Follow-up Phase 3 Data at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
01/05/2019
– 36-month data showed a uveitis eye flare recurrence rate of 56.3% in YUTIQ-treated eyes vs. 92.9% in sham eyes - – Durability of 36-month data and safety support long-term efficacy of YUTIQ - WATERTOWN, Mass., May 01 [...]
C-RAD Web Presentation Interim Report Q1 2019
01/05/2019
Presentation of the report for the first quarter of the fiscal year 2019: Date: Wednesday May 8, 2019 / kl. 13:00 Venue: Online Presentation Topic: C-RAD Interim Report Q1 2019 Procedure: Please register online through [...]
Ambu A/S: Interim report for Q2 2018/19 and for the period 1 October 2018 - 31 March 2019
01/05/2019
Ambu realised organic growth of 14% in Q2 and an increase in earnings of 25%, resulting in an EBIT margin of 24.8%. Organic growth of 15% was posted for H1. "Overall, this was Ambu's best-ever quarter. Growth of 21% in [...]
Motif Bio Signs Agreement with Lamellar Biomedical
01/05/2019
Evaluation of Iclaprim in Combination with LMS-611 for Cystic Fibrosis Lung Infections NEW YORK, May 01, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising [...]
Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker
01/05/2019
LONDON, May 01, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on respiratory diseases, is pleased to announce the appointment [...]

Pages